EchoSolv commercialisation and clinical studies dominate December quarter for Echo IQ

Artificial intelligence and medical technology company Echo IQ (ASX: EIQ) has cited US commercialisation plans and ongoing clinical studies for its EchoSolv heart disease screening platform as its main areas of focus for the three months to December 2022.

Related Keywords

Texas ,United States ,Australia ,Melbourne ,Victoria ,Andrew Grover ,Texas Medical Centre Innovations Bootcamp ,Drug Administration ,National Echo Database Australia ,Harvard Medical School ,Beth Israel Deconess Medical Centre ,Heartx Accelerator ,Texas Medical Centre Innovations ,